GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (LTS:0OIR) » Definitions » EV-to-FCF

Alk-Abello AS (LTS:0OIR) EV-to-FCF : -359.66 (As of Mar. 30, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Alk-Abello AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alk-Abello AS's Enterprise Value is kr32,369 Mil. Alk-Abello AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-90 Mil. Therefore, Alk-Abello AS's EV-to-FCF for today is -359.66.

The historical rank and industry rank for Alk-Abello AS's EV-to-FCF or its related term are showing as below:

LTS:0OIR' s EV-to-FCF Range Over the Past 10 Years
Min: -1561.81   Med: 43.32   Max: 1423.05
Current: -357.2

During the past 13 years, the highest EV-to-FCF of Alk-Abello AS was 1423.05. The lowest was -1561.81. And the median was 43.32.

LTS:0OIR's EV-to-FCF is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 2.91 vs LTS:0OIR: -357.20

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-30), Alk-Abello AS's stock price is kr149.45. Alk-Abello AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr3.780. Therefore, Alk-Abello AS's PE Ratio (TTM) for today is 39.54.


Alk-Abello AS EV-to-FCF Historical Data

The historical data trend for Alk-Abello AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS EV-to-FCF Chart

Alk-Abello AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 354.00 186.44 344.48 78.73 -398.03

Alk-Abello AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.73 61.68 46.92 48.89 -398.03

Competitive Comparison of Alk-Abello AS's EV-to-FCF

For the Biotechnology subindustry, Alk-Abello AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's EV-to-FCF falls into.


;
;

Alk-Abello AS EV-to-FCF Calculation

Alk-Abello AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=32368.961/-90
=-359.66

Alk-Abello AS's current Enterprise Value is kr32,369 Mil.
Alk-Abello AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alk-Abello AS  (LTS:0OIR) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Alk-Abello AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=149.45/3.780
=39.54

Alk-Abello AS's share price for today is kr149.45.
Alk-Abello AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.780.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Alk-Abello AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

No Headlines